Drug Profile

AZD 8076

Alternative Names: AZD-8076

Latest Information Update: 31 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inovio Pharmaceuticals
Developer AstraZeneca; Inovio Pharmaceuticals
Class Antivirals; COVID-19 vaccines; DNA; DNA vaccines; Monoclonal antibodies; Synthetic vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

21 Oct 2025 Efficacy data from a phase I trial in COVID-2019 infections released by Inovio Pharmaceuticals
28 Jul 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA (IM, Injection)
20 Jun 2022 AstraZeneca, Inovio Pharmaceuticals, Indiana University, University of Pennsylvania, and the Wistar Institute enters into RnD agreement for development of DNA encoded monoclonal antibodies

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com